Acadian Asset Management’s Alterity Therapeutics ATHE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$10K Hold
1,863
﹤0.01% 1948
2026
Q1
$6K Sell
1,863
-2,936
-61% -$9.95K ﹤0.01% 1984
2025
Q4
$14K Hold
4,799
﹤0.01% 1918
2025
Q3
$18K Buy
+4,799
New +$23.2K ﹤0.01% 1774
2017
Q4
Sell
-464
Closed -$13K 1569
2017
Q3
$13K Buy
+464
New +$12.6K ﹤0.01% 1257

Other funds holding ATHE

Acadian Asset Management's ATHE Position: Q2 2026 in Review

Acadian Asset Management held its Alterity Therapeutics (ATHE) position steady in Q2 2026 at 1,863 shares worth $10K. The position accounts for ﹤0.01% of the portfolio, ranked #1948.

Acadian Asset Management first reported a position in ATHE in Q3 2017 and has held it in 5 quarters since. The position peaked at $18K in Q3 2025. 22 funds tracked by Wall St. Rank hold ATHE as of Q2 2026.

  • Acadian Asset Management held 1,863 shares of Alterity Therapeutics worth $10K as of Q2 2026.
  • Acadian Asset Management left its Alterity Therapeutics share count unchanged in Q2 2026.
  • Alterity Therapeutics made up ﹤0.01% of Acadian Asset Management's portfolio in Q2 2026, its #1948 holding.
  • Acadian Asset Management first reported a position in Alterity Therapeutics in Q3 2017 and has held it in 5 quarters since.
  • Acadian Asset Management's Alterity Therapeutics position peaked at $18K in Q3 2025.
  • 22 funds tracked by Wall St. Rank held Alterity Therapeutics as of Q2 2026.

Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.